Products
Atorolimumab Biosimilar Monoclonal Antibody (RhD) for Research
Anti-RHD therapeutic antibody (Pre-made Atorolimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Atorolimumab is an immunosuppressive drug directed against the Rhesus factor.[1][2]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-743-1mg | 1mg | 3090 |
| GMP-Bios-INN-743-10mg | 10mg | |
| GMP-Bios-INN-743-100mg | 100mg | |
| GMP-Bios-INN-743-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Atorolimumab Biosimilar, Whole Mab, Anti-Rhd Antibody: Anti-CD240D/DIIIc/HDFNRH/RH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhDCw/RhII/RhK562-II/RhPI therapeutic antibody |
| INN Name | Atorolimumab |
| Target | RHD |
| Format | Whole mAb |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | IgG3 - kappa |
| VD LC | IgG3 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | 0 |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - RHD
1. Protein Blood group Rh(D) polypeptide
2. Gene RHD
3. Organism Homo sapiens (Human)
Function
May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane.
